Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPrime Therapeutics Dojolvi Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentPrime TherapeuticsPolicy N/A

    Dojolvi (triheptanoin) Prior Authorization Program Summary

    Customize your policy alerts

    Sign up for all prime_therapeutics policy alerts

    Know when prime_therapeutics releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and renewal approval for Dojolvi 100% oral liquid for commercial plan members. Coverage is evaluated based on the diagnosis or supported indication, specialist involvement, clinical benefit on renewal, contraindications, and specific use limits for LCFAOD.

    Policy Summary
    PayerPrime Therapeutics
    PolicyDojolvi (triheptanoin) Prior Authorization
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateNov 15, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation showing a qualifying indication, specialist involvement or consultation, and no FDA-labeled contraindication.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 monthsInitial and renewal approval length
    35%Maximum LCFAOD caloric intake
    2 of 3Required LCFAOD diagnostic tests
    RequiredSpecialist involvement

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    AHFS/DrugDex
    Allowed compendia evidence

    Coverage Criteria

    Initial Therapy

    Covered when ALL of the following are met:

    Initial evaluation

    • Qualifying indication

      • LCFAOD indication: The patient has long-chain fatty acid oxidation disorder (LCFAOD), the diagnosis has been confirmed by TWO of the three specified methods, the patient had symptomatic LCFAOD before therapy with the requested agent, the requested agent will not be used with another medium-chain triglyceride product for the requested indication, and the requested agent will not be used for more than 35% of the patient's total prescribed daily caloric intake.Two of three diagnostic methods; not more than 35% of total prescribed daily caloric intake

        The diagnostic methods are disease-specific acylcarnitine elevations, an enzyme activity assay demonstrating deficiency of an enzyme associated with LCFAODs, or genetic testing demonstrating a pathogenic mutation in a gene associated with LCFAODs.

      • FDA-labeled indication: The patient has another FDA-labeled indication for the requested agent and route of administration.
      • Compendia-supported indication: The patient has an indication supported in compendia for the requested agent and route of administration.AHFS or DrugDex evidence level 1, 2a, or 2b
    • Prescriber qualification: The prescriber is a specialist in the area of the patient's diagnosis, such as an endocrinologist, or the prescriber has consulted with a specialist in that area.
    • Contraindication assessment: The patient does not have any FDA-labeled contraindications to the requested agent.

    Continuation Therapy

    Covered when ALL of the following are met:

    Renewal evaluation

    • Previous approval: The patient was previously approved for the requested agent through the plan's prior authorization process.

      Patients not previously approved for the requested agent require initial evaluation review.

    • Clinical benefit: The patient has had clinical benefit with the requested agent.
    • LCFAOD requirements when applicable

      • Combination restriction: The requested agent will not be used in combination with another medium-chain triglyceride product for the requested indication.

    For LCFAOD, Dojolvi must be used without another medium-chain triglyceride product for the requested indication and must not provide more than 35% of the patient's total prescribed daily caloric intake. Initial coverage also requires confirmation of LCFAOD by two of three specified methods, documentation that the disease was symptomatic before therapy, specialist involvement or consultation, and no FDA-labeled contraindication. These LCFAOD-specific use limits continue to apply at renewal.

    Dojolvi caloric intake limit for LCFAOD
    Maximum intakeNot more than 35% of the patient's total prescribed daily caloric intake
    Applies toDojolvi use for long-chain fatty acid oxidation disorder (LCFAOD)
    Combination restrictionDojolvi must not be used in combination with another medium-chain triglyceride product for the requested indication

    Prior Authorization and Provider Requirements

    Prior Authorization

    Initial Prior Authorization Required

    Prior authorization is required before the requested agent can be approved. Submit documentation supporting the patient’s diagnosis or the requested agent’s FDA-labeled or compendia-supported indication, including the route of administration and relevant clinical details.

    • Document the applicable diagnosis or indication and supporting clinical evidence.
    • Identify the prescriber’s specialty or document consultation with a specialist in the area of the patient’s diagnosis.
    • Confirm that the patient has no FDA-labeled contraindication to the requested agent.
    Prior Authorization

    Renewal Prior Authorization

    A renewal prior authorization must be submitted for continued coverage. Renewal requires prior approval through the plan, documented clinical benefit, applicable LCFAOD use-limit compliance, specialist involvement, and confirmation that no FDA-labeled contraindication is present.

    • Submit the renewal before the current 12-month approval period ends.

    Policy Background

    This policy addresses Dojolvi (triheptanoin oral liquid) for patients with long-chain fatty acid oxidation disorder (LCFAOD) and for other FDA-labeled or compendia-supported indications for the requested agent and route of administration. For LCFAOD, coverage requires diagnostic confirmation through laboratory, enzyme activity, or genetic evidence and a history of symptomatic disease before Dojolvi therapy. Initial and renewal approvals are subject to the applicable clinical requirements, with approval issued for 12 months.

    Definitions

    LCFAOD
    AbbreviationLCFAOD
    Full termLong-chain fatty acid oxidation disorder
    Diagnostic confirmationThe diagnosis must be confirmed by two of three specified methods

    Initial Therapy Criteria

    Continuation Criteria

    Renewal Evaluation

    Renewal is approved when ALL of the following are met:

    Continuation therapy

    • Prior approval and clinical benefit: The patient was previously approved for the requested agent through the plan's prior authorization process and has had clinical benefit with the requested agent.

      Patients not previously approved for the requested agent require initial evaluation review.

    • LCFAOD restrictions when applicable

      • Combination restriction: The requested agent will not be used in combination with another medium-chain triglyceride product for the requested indication.
      • Caloric-intake restriction:

    Quantity and Use Limits

    Dojolvi quantity limit
    Maximum amountNot more than 35% of the patient's total prescribed daily caloric intake
    IndicationLong-chain fatty acid oxidation disorder (LCFAOD)
    Approval applicabilityThe limit applies to both initial evaluation and renewal when the diagnosis is LCFAOD
    Policy Summary
    PayerPrime Therapeutics
    PolicyDojolvi (triheptanoin) Prior Authorization
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateNov 15, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation showing a qualifying indication, specialist involvement or consultation, and no FDA-labeled contraindication.
    SourceLink
    On This Page
    Coverage CriteriaPrior Authorization and Provider RequirementsPolicy BackgroundDefinitionsInitial Therapy CriteriaContinuation CriteriaQuantity and Use Limits
    Caloric-intake restriction: The requested agent will not be used for more than 35% of the patient's total prescribed daily caloric intake.Not more than 35% of total prescribed daily caloric intake
  1. Prescriber qualification: The prescriber is a specialist in the area of the patient's diagnosis, such as an endocrinologist, or the prescriber has consulted with a specialist in that area.
  2. Contraindication assessment: The patient does not have any FDA-labeled contraindications to the requested agent.
  3. Document clinical benefit with the requested agent.
  4. For LCFAOD, confirm no combination use with another medium chain triglyceride product and use of the requested agent at no more than 35% of the patient’s total prescribed daily caloric intake.
  5. Identify the prescriber’s specialty or document consultation with a specialist in the area of the patient’s diagnosis.
  6. Confirm that the patient has no FDA-labeled contraindication to the requested agent.
  7. Documentation Required

    LCFAOD Diagnostic Confirmation Required

    For an LCFAOD diagnosis, submit evidence that the diagnosis has been confirmed by at least two specified diagnostic methods.

    • Disease-specific acylcarnitine elevations on a newborn blood spot or in plasma.
    • An enzyme activity assay in cultured fibroblasts or lymphocytes demonstrating deficiency of an enzyme associated with LCFAODs.
    • Genetic testing demonstrating a pathogenic mutation in a gene associated with LCFAODs.
    Denial Risk

    Indication or Diagnosis Must Qualify

    Approval may be denied when the requested use is not supported by the patient’s diagnosis or by an eligible FDA-labeled or compendia-supported indication for the requested agent and route of administration.

    • For LCFAOD, document symptomatic disease before therapy with the requested agent.
    • For another indication, provide an FDA-labeled indication or compendia support from AHFS or DrugDex with level 1, 2a, or 2b evidence.
    Denial Risk

    FDA-Labeled Contraindication

    Approval may be denied when the patient has an FDA-labeled contraindication to the requested agent.

    • Review the agent’s FDA-labeled contraindications during initial and renewal evaluation.
    • Document that no FDA-labeled contraindication is present.
    Denial Risk

    LCFAOD Use Limits

    For LCFAOD, approval may be denied if the requested agent is used with another medium chain triglyceride product for the requested indication or if it exceeds the permitted caloric-intake limit.

    • Do not use the requested agent in combination with another medium chain triglyceride product for the requested indication.
    • The requested agent must account for no more than 35% of the patient’s total prescribed daily caloric intake.
    Denial Risk

    Renewal Eligibility or Benefit Not Established

    Renewal may be denied when the patient was not previously approved through the plan’s prior authorization process or when clinical benefit with the requested agent has not been documented.

    • Patients without prior plan approval require initial evaluation review.
    • Provide documentation demonstrating clinical benefit during renewal review.
    The requested agent will not be used for more than 35% of the patient's total prescribed daily caloric intake.
    Not more than 35% of total prescribed daily caloric intake
  8. Prescriber qualification: The prescriber is a specialist in the area of the patient's diagnosis, such as an endocrinologist, or has consulted with a specialist in that area.
  9. Contraindication assessment: The patient does not have any FDA-labeled contraindications to Dojolvi.